全文获取类型
| 收费全文 | 28591篇 |
| 免费 | 1559篇 |
| 国内免费 | 79篇 |
专业分类
| 耳鼻咽喉 | 386篇 |
| 儿科学 | 2164篇 |
| 妇产科学 | 716篇 |
| 基础医学 | 3350篇 |
| 口腔科学 | 498篇 |
| 临床医学 | 1676篇 |
| 内科学 | 5356篇 |
| 皮肤病学 | 1074篇 |
| 神经病学 | 1471篇 |
| 特种医学 | 1018篇 |
| 外科学 | 4184篇 |
| 综合类 | 943篇 |
| 一般理论 | 17篇 |
| 预防医学 | 1515篇 |
| 眼科学 | 1349篇 |
| 药学 | 2274篇 |
| 中国医学 | 156篇 |
| 肿瘤学 | 2082篇 |
出版年
| 2023年 | 171篇 |
| 2022年 | 395篇 |
| 2021年 | 883篇 |
| 2020年 | 504篇 |
| 2019年 | 595篇 |
| 2018年 | 817篇 |
| 2017年 | 556篇 |
| 2016年 | 762篇 |
| 2015年 | 688篇 |
| 2014年 | 1045篇 |
| 2013年 | 1224篇 |
| 2012年 | 1782篇 |
| 2011年 | 1913篇 |
| 2010年 | 1027篇 |
| 2009年 | 827篇 |
| 2008年 | 1416篇 |
| 2007年 | 1466篇 |
| 2006年 | 1271篇 |
| 2005年 | 1205篇 |
| 2004年 | 1072篇 |
| 2003年 | 979篇 |
| 2002年 | 886篇 |
| 2001年 | 742篇 |
| 2000年 | 694篇 |
| 1999年 | 606篇 |
| 1998年 | 256篇 |
| 1997年 | 188篇 |
| 1996年 | 150篇 |
| 1995年 | 144篇 |
| 1994年 | 122篇 |
| 1993年 | 138篇 |
| 1992年 | 369篇 |
| 1991年 | 394篇 |
| 1990年 | 352篇 |
| 1989年 | 359篇 |
| 1988年 | 312篇 |
| 1987年 | 283篇 |
| 1986年 | 272篇 |
| 1985年 | 285篇 |
| 1984年 | 224篇 |
| 1983年 | 185篇 |
| 1979年 | 241篇 |
| 1978年 | 160篇 |
| 1977年 | 149篇 |
| 1976年 | 139篇 |
| 1975年 | 166篇 |
| 1974年 | 160篇 |
| 1973年 | 178篇 |
| 1972年 | 138篇 |
| 1971年 | 123篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
1.
Apoorva Challa Neeraj Mahajan Seema Sood Arti Kapil Bimal Kumar Das Vishnubhatla Sreenivas Somesh Gupta 《Indian journal of medical microbiology》2022,40(3):433-435
Treatment guidelines for management of uncomplicated gonorrhoeae have been recently modified owing to alarming upsurge in azithromycin resistance. This study investigated the prevalence and genetic determinants of gonococcal azithromycin resistance in India. Four (5.7%) of 70 gonococcal isolates were resistant to azithromycin. Of 16 isolates investigated for molecular mechanisms of resistance, 13 (81.3%) and 6 (37.5%) isolates exhibited mutations in coding and promoter regions of mtrR gene, respectively. However, ermA, ermB and ermC genes or mutations in rrl gene were absent in all isolates. Azithromycin resistance is low in India posing no immediate threat to use of dual-therapy for syndromic management. 相似文献
2.
3.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
4.
Gupta Archana A. Mammo Danny A. Page Michael A. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(1):167-173
Graefe's Archive for Clinical and Experimental Ophthalmology - To evaluate the long-term safety and efficacy of intrastromal bevacizumab for treatment of deep corneal neovascularization in... 相似文献
5.
6.
Uday Yanamandra Prateek Deo Kamal Kant Sahu Ram Vasudevan Nampoothiri Nalini Gupta Anusree Prabhakaran Deb Prasad Dhibhar Alka Khadwal Gaurav Prakash Man Upadesh Singh Sachdeva Deepesh Lad Neelam Varma Subhash Varma Pankaj Malhotra 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):183-189.e1
Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献7.
8.
Stefan Scholz Florian Koerber Kinga Meszaros Rosa Maya Fassbender Bernhard Ultsch Robert R. Welte Wolfgang Greiner 《Vaccine》2019,37(12):1692-1701
Introduction
Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany.Method
A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase of the disease, long-term sequelae, costs for rehabilitation, and public health response. Indirect costs are calculated for the human-capital approach and the friction-cost approach considering productivity losses of patients or parents for the acute phase and long-term sequelae. Publicly available databases from the Federal Statistical Office, the SOEP panel data set, literature, and expert opinion were used as data sources. All future costs beyond the reference year of 2015 were discounted at 3%.Results
The total costs for the hypothetical cohort (343 patients) from a societal perspective are €19.6 million (€57,100/IMD case) using the friction-cost approach and €58.8 million (€171,000/IMD case) using the human-capital approach. Direct costs amount to €18.6 million or €54,300 €/case. Sequelae are responsible for 81% of the direct costs/case.Discussion
The elevated costs/MenB-related IMD case reflect the severity of the disease. The total costs are sensitive to the productivity-loss estimation approach applied. MenB is an uncommon but severe disease; The costs/case reflect the severity of the disease and is within the same magnitude as for human papilloma virus infections. The available literature on sequelae is due to the uncommonness limited and heterogeneous. 相似文献9.
10.